Let's Talk A Little Science!

The following studies demonstrate EHT provides cognitive support

  1. Therapeutic benefits of a component of coffee in a rat model of Alzheimer’s disease. Basurto-Islas G, Blanchard J, Tung YC, Fernandez JR, Voronkov M, Stock M, Zhang S, Stock JB, Iqbal, K. Neurobiol Aging. 2014. (Epub ahead of print). PMID: 25034344
  2. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson’s Disease. Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM. Neurotherapeutics. 2013. 10(1):143-53. PMID: 23296837
  3. Enhanced phosphatase activity attenuates a-synucleinopathy in a mouse model. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM. J Neurosci. 2011. 11:31(19):6963-71. PMID: 21562258

The following studies demonstrates that one or more of the components of Nerium EHT provides cognitive support and/or protection

  1. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. De Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Int J Geriatr Psychiatry. 2012. 27(6):592-600 PMID: 21780182
  2. Oral folic acid and vitamin B12 supplementation to prevent cognitive decline in community dwelling older adults with depressive symptoms – the Beyond Ageing Project: a randomized controlled trial. Walker JG, Batterham PJ, Mackinnon AJ, Jorm, AF, Hickie I, Fenech M, Kljakovic M, Crisp D, Christensen H. Am J Clin Nutr. 2012. Jan; 95(1):194-203. PMID: 22170358
  3. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. PLoS One. 2010. 5(9):e12244.PMID: 20838622
  4. A randomized double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer’s disease. Connelly PJ, Prentice NP, Cousland G, Bonham J. Int J Geriatr Psychiatry. 2008. 23(2):155-60. PMID: 17600848
  5. Enhancement of learning and memory by elevating brain magnesium. Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G. Neuron 2010. 65(2):165-177. PMID: 20152124

The following studies demonstrate PP2A is an important regulator in neurodegeneration and cognition

  1. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Sontag JM, Sontag E. Front Mol Neurosci. 2014. 11;7:16. PMID: 24653673
  2. How it all started: tau and protein phosphatase 2A. Liu C., Gotz J. J Alzheimer’s Dis. 2013. 37(3):483-494. PMID: 23948891
  3. Alpha-Synuclein phosphorylation as a therapeutic target in Parkinson’s disease. Braithwaite SP, Stock JB, Mouradian M. Rev Neurosci. 2012. 23(2):191-198. PMID: 22499677
  4. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3ß. Martin L, Page G, Terro F. Neurochem Int. 2011. 59(2):235-250. PMID: 21672577
  5. Role of PP2A in Alzheimer’s disease. Rudrabhatla P, Pant HC. Curr Alzheimer Res. 2011. 8(6):623-632. PMID: 21605044
  6. PP2A: a novel druggable target for Alzheimer’s disease. Voronkov M, Braithwaite SP, Stock JB. Future Med Chem. 2011. 3(7):821-833. PMID: 21644827
  7. B vitamin deficiency promotes tau phosphorylation through regulation of GSK3ß and PP2A. Nicolia V, Fuso A, Cavallaro RA, Di Luzio A, Scarpa S. J Alzheimers Dis. 2010. 19(3):895-907. PMID: 20157245
  8. The carboxy-terminal fragment of inhibitor-2 of PP2A induces Alzheimer disease pathology and cognitive impairment. Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, Grundke-Iqbal I, Iqbal K. FASEB J. 2010. 24(11):4420-4432. PMID: 20651003
  9. Inhibition of GSK3ß downregulates total tau proteins in cultured neurons and its reversal by the blockade of PP2A. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F. J Brain Res. 2009. 3(1252):66-75. PMID: 19071093
  10. Structural mechanism of demethylation and inactivation of PP2A. Xing Y, Li Z, Chen Y, Stock JB, Jeffrey PD, Shi Y. Cell. 2008. 133:154-63. PMID: 18394995
  11. PP2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. Sontag E, Craig VN, Sontag JM, Arrastia RD, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T. Journal of Neuroscience. 2007. 27(11):2751-2759 PMID: 17360897
  12. Downregulation of PP2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, White C. Journal of Neuropath & Exp Neurology. 2004. 62(10):1080-1091 PMID: 15535135
  13. PP2A methylation: a link between elevated plasma homocysteine and Alzheimer’s Disease. Vafai S, Stock JB. FEBS Lett. 2002. 518, 1-4. PMID: 11997007

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to treat, cure, or prevent any disease.